Strategies for Accelerating the Development of Modified Release Oral Forms
We are dedicated to accelerating the development of new drugs for patients around the world. We provide CRO and CDMO services including formulation development, clinical pharmacology trials, and clinical and commercial manufacturing services to the pharmaceutical and biotech industry. These services are provided either individually or as an integrated service offering via our Translational Pharmaceutics® platform.
Quotient is your answer.
Quotient is your answer.
Quotient is your answer.
Quotient is your answer.
Quotient is your answer.
Our latest updates
News
Quotient and ANA Therapeutics announce partnership to develop drug candidate, ANA001 (niclosamide capsules) as a potential treatment for COVID-19.
Exhibition
Schedule a 1:1 partnering meeting with our CSO, Dr Peter Scholes at the virtual Biotech Showcase 2021 event.
Webinar
This webinar discusses effective strategies being used by biotech and pharmaceutical companies to overcome biopharmaceutic challenges for small molecules in today’s drug development pipeline; and explores alternative approaches for accelerating your early development plan.
Scientific Posters
Gamma scintigraphy is a proven imaging technique used to visualize the in vivo performance of pharmaceutical dosage forms. Combined with pharmacokinetic (PK) analysis, the clinical outcomes provide an understanding of the impact of formulation composition, patient factors and human physiology on in vivo drug absorption. For oral solid dosage forms, technetium-99m and indium-111 are the most commonly used radioisotopes for scintigraphy studies. These radioisotopes can be directly incorporated into the formulations during manufacture or spiking into the drug product. For formulations such as multiparticulates, it would be challenging to radiolabel using these conventional methods. Therefore a specifically designed radiolabelled surrogate with similar physical properties to active multiparticulate was required.
Ask us a question
